Product Overview

The SirPlux Duo Drug-Coated Balloon is powered by an innovative drug delivery platform. Our DCB achieves long-term drug retention in tissue and leaves no implant behind.

Improved Restenosis Prevention

Nanoparticle drug delivery provides sustained drug release and retention in tissue, resulting in stent-like patency and restenosis prevention.

Higher Potency with Less Drug

Uses lower doses of Sirolimus and Paclitaxel to achieve same antiproliferative effects than with each drug separately¹

 

Nothing Left Behind

Preserves long-term arterial health with no risk of late stent thrombosis

 

Positive Health Economics

SirPlux Duo is designed to be less expensive than stent-based coronary treatments, both as a device and as a procedure. It may also lower the cost of re-intervention options.

 

Nanotechnology Benefits

A.N.T.’s proprietary nanotechnology opens the way for more effective endovascular and cardiovascular treatments. SirPlux Duo delivers drugs using 100% biodegradable nanoparticles, deployed directly to the target site.

Our DCB relies on drug-agnostic nanoparticles. These can be adapted to deliver any treatment to any blood vessel, which creates the possibility of novel non-invasive treatments to a host of other conditions.

Unique Competitive Advantages

SirPlux Duo DCB

Competing DCBs and DESs

Drug Delivery and Impact

Delivers two synergistic antiproliferative drugs

Deliver only one antiproliferative drug with limited effects

Risks During Handling

No flaking or loss of drug during handling and delivery

Significant risk of emboli from flaking

Drug Retention

Slow & sustained in-tissue delivery

Low-efficiency, out-of-tissue delivery

API Dosage

12x less SRL and 1.7x less PTX to achieve the same effects

High dosage for inhibiting growth, leading to higher toxicity

Clinical Outcome

Up to 5x lower neointimal growth

Up to 45x less cell proliferation

Noteworthy tissue growth and cell proliferation

References: 1. Data on file at ANT.

Unique Competitive Advantages

SirPlux Duo DCB

Drug Delivery and Impact

Delivers two synergistic antiproliferative drugs

Risks During Handling

No flaking or loss of drug during handling and delivery

Drug Retention

Slow & sustained in-tissue delivery

API Dosage

12x less SRL and 1.7x less PTX to achieve the same effects

Clinical Outcome

Up to 5x lower neointimal growth
Up to 45x less cell proliferation

Competing DCBs and DESs

Drug Delivery and Impact

Deliver only one antiproliferative drug with limited effects

Risks During Handling

Significant risk of emboli from flaking

Drug Retention

Low-efficiency, out-of-tissue delivery

API Dosage

High dosage for inhibiting growth, leading to higher toxicity

Clinical Outcome

Noteworthy tissue growth and cell proliferation

References: 1. Data on file at ANT.